Against the backdrop of deepening population aging, cardiovascular and cerebrovascular diseases have become the “number one killer” threatening national health due to their high incidence, disability, recurrence, and mortality rates. These diseases often occur concurrently, with closely linked pathophysiological mechanisms.
In October 2023, multiple departments including the National Health Commission jointly issued the “Healthy China Action – Cardiovascular and Cerebrovascular Disease Prevention and Treatment Action Implementation Plan (2023-2030)”, which put forward clear requirements for “innovating co-prevention and co-treatment pathways for cardiovascular and cerebrovascular diseases” and “reducing morbidity and mortality risks”. Recently, Shanghai Blue Cross Brain Hospital under Lanson Brain Healthcare, leveraging its advantages in cerebrovascular disease expertise and combining cardiovascular interventional technology, successfully performed multiple “brain-heart co-treatment” combined interventional surgeries, creating a new multidisciplinary one-stop diagnosis and treatment model for “pan-vascular diseases”.
The traditional diagnosis and treatment model usually centers on single diseases, with clinical research and related guidelines also based on individual conditions. This single-discipline, staged treatment model has many limitations such as low efficiency, superimposed risks, conflicting treatment timings, and heavy burden on patients, making it difficult to meet patients’ needs for efficient, precise, and systematic treatment. To break through the bottleneck of the traditional model, Shanghai Blue Cross Brain Hospital has broken disciplinary barriers, deeply integrating neurovascular and cardiovascular interventional technologies. In a single anesthesia and surgery session, multidisciplinary teams collaboratively address coexisting vascular lesions in multiple such as the brain and heart.
The essence of “brain-heart co-treatment” lies in integration and collaboration. The hospital has established a diagnosis and treatment team led by neurointervention experts Professor Xi Gangming and Dr. Wang Guiping, integrating cardiovascular intervention specialists. In the hybrid operating room equipped with advanced DSA (digital subtraction angiography) and other equipment, the team can tailor meticulous and efficient combined surgical plans for individual pan-vascular diseases (such as coexisting cerebrovascular stenosis/aneurysm, coronary artery stenosis, renal artery stenosis, etc.). The value of the successful practice of “brain-heart co-treatment” combined interventional surgery goes far beyond technological breakthroughs. This technology significantly saves patients’ treatment costs, greatly reduces the physical pain and psychological pressure caused by multiple surgeries, efficiently solves coexisting cerebrovascular and cardiovascular problems, truly realizes the “co-treatment” and “co-rehabilitation” of cardiovascular and cerebrovascular diseases, and accelerates patients’ return to healthy lives.
Shanghai Blue Cross Brain Hospital has always been committed to improving diagnosis and treatment levels and upgrading service quality. Its cerebrovascular disease department was selected into the first batch of Shanghai’s specialized influence brands. The department has set up a stroke screening clinic, opened a stroke “green emergency channel”, and built an integrated “first aid-diagnosis-rehabilitation” treatment platform. Both DNT (door-to-needle time) and DPT (door-to-puncture time) have reached advanced domestic levels. The influence of the specialty radiates across the country, with non-local patients accounting for more than 50%.
The hospital will continue to refine its medical skills, build a highland for the diagnosis and treatment of complex and difficult cardiovascular and cerebrovascular diseases, promote the standardized and normalized application of “brain-heart co-treatment” technology, and continuously expand its application potential in the diagnosis and treatment of pan-vascular diseases, providing patients with better quality, more efficient, and more humanized medical options, and contributing solid strength to safeguarding the cardiovascular and cerebrovascular health of the people.
It is reported that Lanson Brain Healthcare attaches great importance to medical technology innovation and strives to make breakthroughs in medical quality, scientific research level, and patient services. In September 2024, the Lanson Brain Healthcare High-Quality Development Promotion Conference proposed “eight measures” to promote high-quality development, among which encouraging its hospitals to carry out advanced technology applications is one of the measures.
In the future, Lanson Brain Healthcare will make full efforts in disciplinary talents, technology application, digital intelligence construction, scientific research, etc., accelerate the cultivation and growth of new medical service capabilities, improve the homogeneous diagnosis and treatment level of its hospitals, and provide higher-quality medical services for more patients.
Related topics:
Aquablation Therapy: New Hope for Men with Enlarged Prostate
40% of perimenopausal women have untreated VMS
New Robotic Prostate Cancer Treatment Causes Fewer Side Effects
